Evidence map›Paper›PMID 36845700›Full record

ArticleFrontiers in oncology2023

Cancer treatment data available in European cancer registries: Where are we and where are we going?

Francesco Giusti, Carmen Martos, Annalisa Trama, Manola Bettio, Arantza Sanvisens, Riccardo Audisio, Volker Arndt, Silvia Francisci, Carine Dochez, Josepa Ribes and 10 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Automated data collection in cancer care: State of play among registries in the United Kingdom and Europe.Health information management : journal of the Health Information Management Association of Australia · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Francesco GiustiEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Carmen MartosEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Annalisa TramaEvaluative Epidemiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Manola BettioEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Arantza SanvisensEpidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia; Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
Riccardo AudisioDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Göteborg, Sweden.
Volker ArndtEpidemiological Cancer Registry Baden-Württemberg (M110) & Unit of Cancer Survivorship (C071), Division of Clinical Epidemiology and Aging Research (C070), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Silvia FrancisciNational Centre for Disease Prevention and Health Promotion, Istituto Superiore di Sanità, Rome, Italy.
Carine DochezBelgian Cancer Registry, Brussels, Belgium.
Josepa RibesCatalan Cancer Plan, Department of Health of Catalonia, Hospitalet del Llobregat, Barcelona, Spain.
Laura Pareja FernándezCatalan Cancer Plan, Department of Health of Catalonia, Hospitalet del Llobregat, Barcelona, Spain.
Anna GavinNorthern Ireland Cancer Registry, Centre for Public Health, Queen's University Belfast, Belfast, Ireland.
Gemma GattaEvaluative Epidemiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Rafael Marcos-GrageraEpidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia; Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
Yolande LievensDepartment of Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium.
Claudia AllemaniCancer Survival Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Roberta De AngelisDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Otto VisserDepartment of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands.
Liesbet Van EyckenBelgian Cancer Registry, Brussels, Belgium.
ENCR Working Group on Treatment Data Harmonisation

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Population-based cancer registries are responsible for collecting incidence and survival data on all reportable neoplasms within a defined geographical area. During the last decades, the role of cancer registries has evolved beyond monitoring epidemiological indicators, as they are expanding their activities to studies on cancer aetiology, prevention, and quality of care. This expansion relies also on the collection of additional clinical data, such as stage at diagnosis and cancer treatment. While the collection of data on stage, according to international reference classification, is consolidated almost everywhere, data collection on treatment is still very heterogeneous in Europe. This article combines data from a literature review and conference proceedings together with data from 125 European cancer registries contributing to the 2015 ENCR-JRC data call to provide an overview of the status of using and reporting treatment data in population-based cancer registries. The literature review shows that there is an increase in published data on cancer treatment by population-based cancer registries over the years. In addition, the review indicates that treatment data are most often collected for breast cancer, the most frequent cancer in women in Europe, followed by colorectal, prostate and lung cancers, which are also more common. Treatment data are increasingly being reported by cancer registries, though further improvements are required to ensure their complete and harmonised collection. Sufficient financial and human resources are needed to collect and analyse treatment data. Clear registration guidelines are to be made available to increase the availability of real-world treatment data in a harmonised way across Europe.

Indexed as

big datacancer registrycancer registry datacancer treamentdata harmonisationEuropequestionnaire

Identifiers

PMID36845700
PMCPMC9944949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.